Thomas Sundermeier

Thomas Sundermeier's work experience begins in 2008 at McGill University, where they worked as a Postdoctoral Fellow until 2010. From 2010 to 2016, they were a Research Associate at Case Western Reserve University, focusing on uncovering the physiology and gene regulatory interactions underlying visual system pathologies. During this time, they authored six peer-reviewed publications, including two review articles, and earned an F32 individual postdoctoral fellowship from the NIH.

In 2016, Thomas Sundermeier joined Covance as a Start-Up Associate Project Manager. In this role, they managed all aspects of clinical study start-up for global clinical trials, with experience in oncology, myelofibrosis, chronic sinusitis, diabetes, and in vitro diagnostics. Thomas ensured the on-time activation of sites in Europe, Asia, and North America. Additionally, they served as a Specialist II, Document Review at Covance, where they performed quality control on clinical study protocols, informed consent documents, recruitment materials, and site regulatory documents, involving more than 30 clinical study protocols and more than 100 informed consent documents.

From 2020 to 2021, Thomas Sundermeier worked at Syneos Health as a Protocol Manager/Global Trial Manager, overseeing global trials and managing protocols. In 2021, they joined ICON plc as a Global Studies Manager, and in 2022, they moved to Thermo Fisher Scientific as a Senior Clinical Team Manager. Thomas is currently working at ONO PHARMA USA as a Senior Manager Clinical Scientist, starting in May 2023.

Thomas Sundermeier has a strong education background in the field of biology. Thomas obtained their Bachelor's Degree in Zoology from Kent State University in 1999. Thomas then went on to pursue their Master's Degree in Biology at Stony Brook University, which they completed in 2001. Thomas continued their education at Stony Brook University and received their Doctor of Philosophy (Ph.D.) in Molecular and Cellular Biology in 2007.